OBJECTIVES: Irritable bowel syndrome (IBS) is a common disorder and available therapies
have limited efficacy. Mucosal inflammation and alterations in gut microflora may contribute …

OBJECTIVES: There has been no definitive synthesis of the evidence for any benefit of
available pharmacological therapies in opioid-induced constipation (OIC). We conducted a …

Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder that significantly
reduces patients' quality of life. Advances in diagnostic testing and in therapeutic options for …

METHODS: We searched PubMed and Embase for randomized controlled trials of≥ 4-week
duration that evaluated OTC preparations between 2004 and 2020. Studies were scored …

Background: Changes in the receptor profile between primary and metastatic breast cancer
tissue have been suggested. The degree of hormone receptor discordance in archival …

Background & Aims There is an urgent need for safe treatments for irritable bowel syndrome
(IBS) that relieve treatment-refractory symptoms and their societal and economic burden …

Background & Aims Irritable bowel syndrome (IBS) has significant mental and physical
comorbidities. However, little is known about the day-to-day burden these comorbidities …

OBJECTIVES: Two identical, phase 3, randomized, double-blind, placebo-controlled trials
evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome …

Objective Opioids are increasingly prescribed in the West and have deleterious GI
consequences. Pharmacological therapies to treat opioid-induced constipation (OIC) are …

BACKGROUND: There is a need for safe and effective IBS treatments that provide
immediate and sustained improvement of IBS symptoms, particularly among more severe …